Cassava Sciences Inc
Suletud
SektorTervishoid
2.1
Ülevaade
Aktsiahinna muutus
24h
Min
2.1
Max
2.1
Sissetulek | -1.7M -13M |
|---|---|
Müük | 840K 840K |
Kasumimarginaal | -1,492.738 |
Töötajad | 30 |
EBITDA | -39M -50M |
Turukapital | -4.3M 142M |
|---|---|
Eelmine avamishind | 2.1 |
Eelmine sulgemishind | 2.1 |
Tehniline skoor
By Trading Central
Kindlus
Weak Bearish Evidence
Cassava Sciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Cassava Sciences Inc Prognoos
Finantsandmed
$
Ettevõttest Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.